Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

Yearbook of Dermatology and Dermatologic Surgery ◽

10.1016/s0093-3619(09)79428-6 ◽

2010 ◽

Vol 2010 ◽

pp. 138-139

Author(s):

J. Weinberg

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Crossover Trial ◽

Interleukin 12 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1157934.618001 ◽

2009 ◽

Author(s):

Lars Klareskog ◽

Anca Catrina

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Crossover Trial ◽

Interleukin 12 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

10.1016/s0140-6736(09)60140-9 ◽

2009 ◽

Vol 373 (9664) ◽

pp. 633-640 ◽

Author(s):

Alice Gottlieb ◽

Alan Menter ◽

Alan Mendelsohn ◽

Yaung-Kaung Shen ◽

Shu Li ◽

...

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Crossover Trial ◽

Interleukin 12 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1108987.566149 ◽

2008 ◽

Author(s):

Johann Gudjonsson

Keyword(s):

Monoclonal Antibody ◽

Controlled Trial ◽

Interleukin 12 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

10.1016/s0140-6736(08)60726-6 ◽

2008 ◽

Vol 371 (9625) ◽

pp. 1675-1684 ◽

Author(s):

Kim A Papp ◽

Richard G Langley ◽

Mark Lebwohl ◽

Gerald G Krueger ◽

Philippe Szapary ◽

...

Keyword(s):

Monoclonal Antibody ◽

Controlled Trial ◽

Interleukin 12 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

OP0218 Efficacy and safety results of guselkumab, an anti-il23 monoclonal antibody, in patients with active psoriatic arthritis over 24 weeks: a phase 2a, randomized, double-blind, placebo-controlled study

10.1136/annrheumdis-2017-eular.1164 ◽

2017 ◽

Author(s):

A Deodhar ◽

A Gottlieb ◽

W-H Boehncke ◽

B Dong ◽

Y Wang ◽

...

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

228. Secukinumab, A Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicentre, Double-Blind, Placebo-Controlled Study

Rheumatology ◽

10.1093/rheumatology/kev089.115 ◽

2015 ◽

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Radiographic Progression ◽

Safety Data ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 17A

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718257967.793494565 ◽

2014 ◽

Author(s):

Christian Jorgensen ◽

Yves-Marie Pers

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Therapy ◽

Necrosis Factor

Download Full-text

Long‐term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through 2 Years: Results from a Phase 3, Randomized, Double‐blind, Placebo‐controlled Study Conducted in Biologic‐naïve Patients with Active Psoriatic Arthritis

Arthritis & Rheumatology ◽

10.1002/art.42010 ◽

2021 ◽

Author(s):

Iain B. McInnes ◽

Proton Rahman ◽

Alice B. Gottlieb ◽

Elizabeth C. Hsia ◽

Alexa P. Kollmeier ◽

...

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Term Efficacy ◽

Download Full-text

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

10.1016/s0140-6736(15)61134-5 ◽

2015 ◽

Vol 386 (9999) ◽

pp. 1137-1146 ◽

Author(s):

Iain B McInnes ◽

Philip J Mease ◽

Bruce Kirkham ◽

Arthur Kavanaugh ◽

Christopher T Ritchlin ◽

...

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 17A ◽

Download Full-text

A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis

Current Medical Research and Opinion ◽

10.1185/030079907x182112 ◽

2007 ◽

Vol 23 (5) ◽

pp. 1081-1092 ◽

Author(s):

Alice B. Gottlieb ◽

Kevin D. Cooper ◽

Thomas S. McCormick ◽

Eiko Toichi ◽

Daniel E. Everitt ◽

...

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase 1 ◽

Controlled Study ◽

Interleukin 12 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text